ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELVN vs IDYA // DIVIDEND YIELD & FCF PAYOUT SAFETY

Enliven Therapeutics Inc. (NASDAQ) VS. IDEAYA Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: ELVN 3 — IDYA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELVN VS. IDYA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELVN IDYA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -26.20% -13.80% -12.40 IDYA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.13% -2.31% +0.18 ELVN /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -52.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 21.49 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 IDYA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.0 34.6 +16.47 ELVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.30B $3.17B $129.5M ELVN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELVN REV IDYA REV ELVN GROSS % IDYA GROSS % ELVN FCF IDYA FCF
FY 2025 $0 $218.7M — — -$70.3M -$73.5M
FY 2024 $0 $7.0M — — -$73.2M -$251.4M
FY 2023 $0 $23.4M — — -$61.3M -$115.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELVN // BETA —
IDYA // BETA —